OPINION
NEWS
REGIONS
WORLD
BUSINESS
SPORTS
ENTERTAINMENT
LIFESTYLE
THE SUNDAY TIMES
SPECIAL FEATURES
SPECIAL SECTIONS
TMT NEWSWIRE
LEGAL ADVICE
FAST TIMES
CAMPUS PRESS
VIDEOS
EXPATS & DIPLOMATS
PHOTOS
PODCASTS
BUSINESS FORUM
RESOURCES
MARKET OVERVIEW
EXAM RESULTS
WEATHER
CLASSIFIEDS
TMT CSI
TMT DIGITAL EDITION
GAMES
TMT 125TH ANNIVERSARY
QUIZZES
World > Americas & EMEA
Eli Lilly weight loss drug beats Ozempic in head-to-head study
By Agence France-Presse
Jul 09, 2024 1:34 pm

WASHINGTON, D.C. — Patients taking Eli Lilly's new drug Mounjaro achieved significantly greater weight loss than those on Novo Nordisk's Ozempic, a head-to-head study published Monday showed.

Researchers analyzed the electronic health records of more than 18,000 US patients between May 2022 and September 2023 to compare outcomes among those receiving the two injected medicines, and published the results in JAMA Internal Medicine.

Related Articles

Hezbollah vows revenge after deadly pager blasts

Trump: Only 'consequential presidents get shot at'

UK's Princess of Wales makes tentative return to work

EU: Deadly floods, fires prove climate breakdown

Instagram tightens protection for teens

Israel adds Lebanon front to war aims

Man admits guilt in drugging, raping wife